Deep learning for cancer type classification and driver gene identification

Zexian Zeng\textsuperscript{1,2}, Chengsheng Mao\textsuperscript{1}, Andy Vo\textsuperscript{3}, Xiaoyu Li\textsuperscript{4}, Janna Ore Nugent\textsuperscript{5}, Seema A. Khan\textsuperscript{6*}, Susan E. Clare\textsuperscript{7*} and Yuan Luo\textsuperscript{1*}

From The International Conference on Intelligent Biology and Medicine (ICIBM) 2020 Virtual. 9-10 August 2020

Abstract

\textbf{Background:} Genetic information is becoming more readily available and is increasingly being used to predict patient cancer types as well as their subtypes. Most classification methods thus far utilize somatic mutations as independent features for classification and are limited by study power. We aim to develop a novel method to effectively explore the landscape of genetic variants, including germline variants, and small insertions and deletions for cancer type prediction.

\textbf{Results:} We proposed DeepCues, a deep learning model that utilizes convolutional neural networks to unbiasedly derive features from raw cancer DNA sequencing data for disease classification and relevant gene discovery. Using raw whole-exome sequencing as features, germline variants and somatic mutations, including insertions and deletions, were interactively amalgamated for feature generation and cancer prediction. We applied DeepCues to a dataset from TCGA to classify seven different types of major cancers and obtained an overall accuracy of 77.6%. We compared DeepCues to conventional methods and demonstrated a significant overall improvement ($p < 0.001$). Strikingly, using DeepCues, the top 20 breast cancer relevant genes we have identified, had a 40% overlap with the top 20 known breast cancer driver genes.

\textbf{Conclusion:} Our results support DeepCues as a novel method to improve the representational resolution of DNA sequencings and its power in deriving features from raw sequences for cancer type prediction, as well as discovering new cancer relevant genes.

\textbf{Keywords:} Convolutional neural network, Cancer, Classification, Whole-exome sequencing, Somatic mutation, Germline variants

Background

The majority of cancer driver gene studies have been focusing on the identification of individual somatic point mutations [1, 2]. However, somatic mutations are often highly heterogeneous between cancer genomes, even within the same type of cancer, and...
only represent for a small portion of the genome variations [3]. While many methods attempted to address the complex mutational heterogeneity in cancer, driver gene identification still remains a challenge due to the limited capability in integrating other genome components for integrative study [4–8]. Other genome components, such as nonsense mutations of insertions and deletions, as well as germline variation, were largely ignored in the past but have been recently highlighted to play a significant role for cancer development [9–11]. Genome components, including somatic mutations, germline variants, insertions and deletions, when studied together, especially in an interactive term, give rise to the challenges of model complexity and study power [12].

Due to the limitation of analysis power, methods including Bayesian classifier [13], regression models [14, 15], and KNN [16] are not optimal in handling such high-dimensional features interactively. To circumvent these challenges, labor intensive feature engineering using prior knowledge need to be performed prior to modeling [17]. These conventional learning algorithms rely heavily on data representations and are typically designed by domain experts. The complexity of the human genome and the amount of required human effort make it difficult to derive meaningful features [18, 19], whereas deep learning can automatically learn a good feature representation [20]. Deep learning has recently emerged with the advances in big data with the power of parallel computing and sophisticated algorithms. Furthermore, deep learning models are exponentially more efficient than conventional models in learning intricate patterns from high-dimensional raw data with little guidance [20–23]. Typically, convolutional neural networks (CNNs) computes convolution on small regions by sharing parameters between regions [24], which allows training models on large DNA sequences. Recent examples of exploring the application of CNNs within raw sequencing data include DeepBind [25], DanQ [26], DeepSEA [27], DeepCpG [28].

Inspired by the successful applications of deep learning models in genomics data, and in an attempt to study somatic mutations, germline variants, insertions and deletions collectively and interactively, we propose to utilize deep learning models to study the tumor raw sequences, namely Deep learning for disease Classification using exome sequencings (DeepCues). Specifically, we propose to use a CNNs model to utilize tumor raw DNA sequences for cancer type classification and more importantly, relevant gene identification. In addition to raw tumor sequence, we also investigated the utility of germline DNA sequences. Collectively, we have identified a subset of genes that are relevant for each cancer development. In a pilot study utilizing 4174 samples across seven major cancer types from The Cancer Genome Atlas (TCGA), we were able to achieve an accuracy of 77.6% in predicting cancer types using the raw tumor sequences. Germline variants dominant somatic mutations number-wise, strikingly, in the attempt of utilizing germline raw sequences only, we were able to achieve an accuracy of 73.9%. Using the trained models, we have identified several known cancer driver genes, along with a list of genes that have not been previously reported as cancer driver genes.

Results
The following cancers were analyzed: brain cancer, breast cancer, colorectal cancer, kidney cancer, lung cancer, prostate cancer, and uterus cancer. Germline and somatic mutations from 4174 samples across seven major cancer types were obtained from the
To construct raw sequences for each cancer sample, we merged the reference genome sequence with the identified germline variants and somatic mutations, individually or in combination. To prepare the germline variants, aligned sequencing data derived from blood or adjacent normal tissues were recalibrated, and variants were called using HaplotypeCaller from GATK package [30]. SnpEFF was used for functional annotation [31], and variants annotated with moderate effects were missense mutations and in-frame shifts; nonsense mutations were annotated as high effects. In parallel, somatic mutations for the matched samples were obtained directly from TCGA and the same functional annotation processes were performed. In total, 4600 virtual machines were utilized for 119,000 CPU hours for these tasks. Overall, we identified 45,119,052 germline variants and 957,115 somatic mutations from the 4174 matched samples (Table 1).

As a pilot study, we derived features only from genes that have been implicated in cancers using a list of 719 consensus genes (Additional file 1: Table S1) from the Catalogue of Somatic Mutations in Cancer (COSMIC), which is a mutation catalogue with comprehensive mutation information curated from about 542,000 tumor samples [32]. In our dataset, these consensus genes corresponded to 985 canonical transcripts (Additional file 2: Table S2) and thus, the transcripts were used to train and evaluate our proposed models. To construct raw sequences for each sample, sequences in RefSeq database was started as references (Fig. 1a). The RefSeq database was named as consensus matrix. This consensus matrix consists of 24,286 transcripts. The average length of these sequences were 3375 bases. For each individual, the identified germline variants were constructed into the consensus matrix, forming a germline raw sequence (Fig. 1b). Once a germline raw sequence was formed for each sample, somatic mutations were then constructed in the germline raw sequence, forming a cancer raw sequence (Fig. 1c). It has been suggested that mutations prefer certain codons and the distance between amino acid changes have been described [33]. Moreover, the position within the codon where the mutation occurs is critical. To incorporate codon information into our model features, one hot encoding was applied with every three nucleotides and was encoded as a binary unit. The combination of

| Cancer               | Cancer # | Blood # | Adjacent normal # | Germline moderate | Germline high | Somatic moderate | Somatic high |
|----------------------|----------|---------|-------------------|-------------------|---------------|-----------------|--------------|
| Breast cancer        | 959      | 936     | 23                | 10,911 (71)       | 641 (5)       | 65 (10)         | 16 (3)       |
| Colorectal cancer    | 420      | 395     | 25                | 10,331 (241)      | 621 (15)      | 293 (79)        | 81 (18)      |
| Brain cancer         | 763      | 763     | 0                 | 9572 (55)         | 550 (3)       | 94 (30)         | 23 (6)       |
| Uterus cancer        | 530      | 507     | 23                | 10,894 (103)      | 650 (7)       | 645 (152)       | 160 (28)     |
| Lung cancer          | 730      | 713     | 17                | 9717 (37)         | 555 (2)       | 217 (15)        | 43 (3)       |
| Kidney cancer        | 332      | 332     | 0                 | 10,882 (124)      | 634 (8)       | 51 (6)          | 14 (1)       |
| Prostate cancer      | 440      | 440     | 0                 | 9744 (53)         | 558 (4)       | 34 (22)         | 7 (3)        |

Variants annotated with moderate effects are defined as missense mutations and in-frame shifts; variants annotated as high effects are defined as nonsense mutations

*Number in parenthesis is standard deviation (SD)
four nucleotides (A, C, T, and G) results in a vector with 64 dimensions to represent each codon combination.

A convolutional framework that consists of multiple layers was used in our study (Fig. 2). The framework has three components: input layer (Fig. 2a), encoder layer (Fig. 2b) (multiple convolutional and dense layers), and fully connected layer (Fig. 2c). We first trained convolutional neural networks (CNNs) using the 985 pathogenetic transcripts and calculated overall classification accuracy for each cancer type. Using only the germline raw sequence as input (Method), we achieved an overall accuracy of 73.9% (SE = 0.7%) (SE standard error). Using the cancer raw sequence as input, the achieved...
overall accuracy was 77.6% (SE = 0.9%). To compare our method to other conventional cancer classification methods and to benchmark our results, we calculated baseline accuracies using logistic penalized linear regression and linear SVM, which are among the most widely utilized methods for cancer classification. We also evaluated more advanced models including Gradient Boosting Decision Tree (GBDT) and Multiple Layer Perceptron (MLP). Logistic penalized linear regression resulted in an overall accuracy of 51.5% (SE = 0.5%) and 65.5% (SE = 0.3%) using the germline and cancer data, respectively; linear SVM yielded an overall accuracy of 49.4% (SE = 0.4%) and 58.6% (SE = 0.3%). Likewise, Gradient Boosting Decision Tree (GBDT) achieved an overall accuracy of 62.1% (SE = 0.24%) and 61% (SE = 0.21%) (Fig. 3). Using sequence data as input, MLP model
achieved an overall accuracy of 69.2% (SE = 0.23) and 74% (SE = 0.89). Using the same input information, our proposed method significantly outperformed the conventional methods ($p < 0.001$).

For each cancer type, classification precision, recall, and f-measure were characterized (Table 2). Of note, multiclass data will be treated as if binarized under a one-vs-rest transformation. Using only germline raw sequence, we found breast cancer and colorectal cancer yielded the highest F-measure scores. Using tumor raw sequence data, we found breast cancer, colorectal cancer, and brain cancer had the highest F-measure scores. Multilabel confusion matrix averaged between the 10 runs were used to evaluate the effectiveness of our proposed method (Table 3). In our proposed model, tumor raw sequence is a combination of somatic mutations and germline raw sequences. Adding the somatic mutation data increased F-measures for breast cancer, brain cancer, and uterus cancer significantly ($p = 6.7E−03, 3.8E−06, and 1.9E−02$ respectively).

In an attempt to identify novel cancer driver genes, we integrated an additional 985 transcripts to our current feature pools. When using only the germline raw sequence as input features, we achieved an overall accuracy of 82.7% (SE = 0.6%). Using the raw cancer sequence as input, we achieved an overall accuracy of 80.0% (SE = 0.9%). Similarly, for each type of cancer, we calculated precision, recall, and F-measure using either the

---

**Table 2** Precision and recall for our proposed model

| Cancer Type | Germline Sequence | | | Cancer Sequence | | |
|-------------|-------------------|----------------|------------------|-------------------|------------------|------------------|
|             | Precision (%)     | Recall (%)     | F-measure (%)    | Precision (%)     | Recall (%)     | F-measure (%)    |
| Breast      | 81.9 (2.7)        | 83.4 (4.2)     | 81.4 (1.8)      | 85.6 (2.0)        | 90.7 (1.8)     | 87.8 (1.1)      |
| Colorectal  | 85.9 (1.9)        | 83.9 (2.1)     | 84.6 (0.8)      | 84.7 (4.5)        | 87.1 (2.6)     | 84.7 (2.1)      |
| Brain       | 73.0 (1.5)        | 66.5 (4.3)     | 68.5 (1.9)      | 87.5 (2.7)        | 78.4 (2.0)     | 82.2 (0.9)      |
| Uterus      | 76.3 (4.9)        | 62.7 (6.9)     | 64.2 (3.9)      | 85.3 (1.8)        | 68.2 (3.3)     | 75.1 (1.7)      |
| Lung        | 64.8 (3.2)        | 75.5 (4.7)     | 67.7 (1.5)      | 70.3 (4.9)        | 78.4 (5.5)     | 71.2 (2.0)      |
| Kidney      | 76.9 (2.5)        | 71.5 (2.8)     | 73.4 (1.1)      | 77.6 (4.7)        | 68.7 (5.9)     | 69.5 (2.3)      |
| Prostate    | 70.8 (4.2)        | 55.7 (6.0)     | 58.9 (3.2)      | 65.6 (5.5)        | 50.5 (9.7)     | 49.1 (5.9)      |

The experiment is replicated for 10 times and the number in parenthesis is standard error. The bolded number are those that significantly improved in cancer sequence compared to germline sequence.
Using only germline data, we found breast cancer and colorectal cancer had the highest F-measure scores. Using both germline and somatic mutation data, we found breast cancer, colorectal, and uterus cancer had the highest F-measure scores. Consistently, best performances were found within breast cancer and colorectal cancer in both models.

Using the coefficients derived from the fully connected layer, the model can be extended to prioritize genes that are relevant for each cancer type. The analysis was

| Predicted class cancer sequence | Germline sequence | Cancer sequence |
|---------------------------------|-------------------|-----------------|
| Predicted                      | Positive | Negative | Positive | Negative |
| True                            |          |          |          |          |
| Breast                          | 161      | 31       | 169      | 22       |
| Negative                        | 36       | 608      | 39       | 604      |
| Colorectal                      | 73       | 11       | 72       | 11       |
| Positive                        | 15       | 737      | 8        | 743      |
| Negative                        | 124      | 29       | 100      | 53       |
| Uterus                          | 64       | 42       | 62       | 44       |
| Positive                        | 22       | 708      | 16       | 713      |
| Negative                        | 88       | 58       | 94       | 52       |
| Lung                            | 33       | 657      | 60       | 628      |
| Positive                        | 48       | 19       | 49       | 19       |
| Negative                        | 18       | 751      | 26       | 741      |
| Kidney                          | 57       | 31       | 50       | 38       |
| Positive                        | 30       | 719      | 36       | 710      |
| Negative                        |          |          |          |          |

The number is average of the 10 runs for test set prediction

| Predicted                      | Germline sequence | Cancer sequence |
|---------------------------------|-------------------|-----------------|
|                                | Precision | Recall | F-measure | Precision | Recall | F-measure |
| Breast                          | 87.1% (2.8%) | 91.9% (1.6%) | 89.0% (1.2%) | 89.1% (1.6%) | 87.2% (2.2%) | 87.8% (0.7%) |
| Colorectal                      | 87.8% (1.7%) | 94.0% (1.6%) | 90.6% (0.8%) | 86.1% (3.8%) | 90.8% (2.9%) | 87.5% (2.2%) |
| Uterus                          | 90.0% (1.8%) | 72.8% (6.8%) | 78.0% (5.5%) | 84.9% (3.1%) | 71.4% (2.8%) | 76.6% (1.0%) |
| Brain                           | 88.3% (4.4%) | 58.6% (5.2%) | 67.9% (2.2%) | 77.3% (2.5%) | 75.9% (3.5%) | 75.6% (1.5%) |
| Lung                            | 69.1% (4.9%) | 79.9% (7.2%) | 69.8% (2.7%) | 73.7% (3.1%) | 75.6% (4.0%) | 73.4% (1.8%) |
| Kidney                          | 81.9% (2.7%) | 81.3% (2.0%) | 81.3% (1.5%) | 70.0% (3.8%) | 76.0% (5.0%) | 71.2% (3.3%) |
| Prostate                        | 76.4% (6.1%) | 67.3% (7.2%) | 66.0% (3.7%) | 72.2% (2.7%) | 65.5% (3.5%) | 68.1% (2.3%) |

The experiment is replicated for 10 times and the number in parenthesis standard error. The bolded number are those that significantly improved in cancer sequence compared to germline sequence

germline raw sequence or the cancer raw sequence (Table 4). Using only germline data, we found breast cancer and colorectal cancer had the highest F-measure scores. Using both germline and somatic mutation data, we found breast cancer, colorectal, and uterus cancer had the highest F-measure scores. Consistently, best performances were found within breast cancer and colorectal cancer in both models.

Using the coefficients derived from the fully connected layer, the model can be extended to prioritize genes that are relevant for each cancer type. The analysis was
repeated 10 times with different initial seeds and top 20 genes were labeled in each replicate. The studied genes were subsequently ranked by frequency among all replicates. Top ranked genes were considered as cancer relevant genes and were summarized in Additional files 4–7: Table S4–S7. As a result of breast cancer relevant gene discovery, strikingly, 8 of the top 20 genes overlapped with the COSMIC breast cancer top 20 genes when we use cancer raw sequences as input. The high consensus rate (40%) partially validated that our method was effective in identifying cancer relevant genes. In addition, we have identified cancer relevant genes that have not been previously explored for breast cancer (Table 5).

**Discussion**

The development of high throughput sequencing technology has enabled the cataloging of large-scale genetic information. To help improve cancer diagnosis and targeted therapies, cancer type classification methods are continually being upgraded. Traditionally, the majority of classification methods based on DNA sequencing data has relied on studying single point somatic mutations with various regression models [34–36]. Mutations involving insertions and deletions as well as germline mutations have been largely ignored due to the high dimensionality problem. Given that many methods are already limited in their ability to study so many variables, it has been even more challenging to integrate these variables and study them interactively. To deal with these challenges, groups have proposed aggregating mutations on a gene level to be studied as a feature [35, 37–39]. Mutations within genes

---

**Table 5** The top 20 genes relevant genes with breast cancer derived from the 985 pathogenetic transcripts and the 1970 transcripts

| 985 transcripts | 1970 transcripts |
|-----------------|------------------|
| **Germline**    | **Cancer**       | **Germline**    | **Cancer**       |
| TCF3            | GATA3            | TCF3            | FOXP1            |
| FOXP1           | APC              | RNF213          | SPATA31A3        |
| LEF1            | PIK3CA           | FOXP1           | PAFAH1B2         |
| PAFAH1B2        | PAFAH1B2         | PALB2           | DOCK2            |
| BLM             | PPP2R1A          | PALB2           | CCNE1            |
| PPFIBP1         | CDH1             | ADAM23          | ANK1             |
| PALB2           | CHD2             | NCOA4           | ITK              |
| MUC4            | RUNX1            | KC6             | TCF3             |
| CCDC6           | MSH6             | PALB2           | CCNE1            |
| LIFR            | CNBD1            | AMOT            | FOXP1            |
| MITF            | KMT2C            | LEF1            | ABHD13           |
| CCNE1           | ARID1A           | CPEB2           | SPATA31A3        |
| ZCCHC8          | TBX3             | SPATA31D1       | XPO6             |
| TP53            | KRAS             | IL21            | FRYL             |
| FOXO4           | CHD4             | BLM             | RFC5             |
| EBF1            | KMT2D            | ITK             | SDHAF2           |
| TERT            | NRAS             | ZNF507          | POU4F1           |
| GMPS            | MAP3K1           | CCDC6           | PICALM           |
| CCNC            | HLA-A            | TERT            | LEF1             |

The bold genes in the 985 transcripts are the ones found in COSMIC top 20 genes. The bold genes in the 1970 transcripts are the ones in the unknown transcripts.
have also been proposed to be studied within a matrix as inputs for machine learning methods [40–43]. In our study, we have proposed a novel method, DeepCues. DeepCues utilized the raw sequence as inputs, which by nature integrates all somatic mutations and germline variants, and also INDELs, to be studied as inputs in a joint manner. Convolutional Neural Networks (CNNs) were then applied to train classifiers for cancer type classification. Furthermore, we have included a fully connected layer to allow for relevant gene discovery to help characterize genes and pathways important for multiple cancers.

As a pilot study, we retrieved germline and somatic DNA sequencing data from matched samples across seven types of cancer and used DeepCues to perform cancer type classification. Of note, the COSMIC has combined genome-wide sequencing results from 542,000 tumors with complete manual curation of 23,489 individual publications [32, 44]. Using 985 known pathogenic transcripts as input, we obtained 73.9% and 77.6% accuracy using germline raw sequencing and cancer sequencing data as inputs, respectively. In our results, DeepCues was also found to significantly outperform conventional methods (p < 0.01). Consistent with somatic mutations playing a large role in cancer [45], integration of somatic mutations together with germline data significantly improved overall accuracy (p = 0.005) using the 985 known pathogenetic transcripts. Integration of somatic data significantly increased accuracy for breast cancer (p = 6.6E–03), brain cancer (p = 3.8E–06), and uterine cancer (p = 1.92E–02), suggesting somatic mutations play a relatively larger role in these cancers. Following the integration of additional 985 unknown transcripts into the model, we were able to boost overall accuracy to 82.7% and 80.0% for germline sequences and cancer sequences, respectively. As an observation, after integrating the additional 985 transcripts, cancer raw sequences were not superior to germline sequencing, suggesting that the addition of somatic mutations was not informative for cancer type prediction. This observation is partially due to the fact that traditional cancer driver gene research’s focus on somatic mutations. As a result, the 985 additional transcripts that were not previously identified as cancer driver genes, are most likely not enriched for cancer relevant somatic mutations. Conventional methods are limited regarding germline variation and their interactive role in cancer due to a large number of variables and complexity issues. In our study, we were able to obtain reasonable accuracy performances using the germline raw sequence only as an input. This suggests that germline variation may be more important than previously reported based on prior methods [34]. More specifically, we found that breast cancer and colorectal cancer have the best performance using only germline information, suggesting that these two cancers probably confer higher heritability compared to others. Studies have reported high familial heritability in breast cancer and colorectal cancer too [46]. Using a fully connected layer in our framework, we identified relevant known and unknown pathogenic genes. For the 20 genes we have identified to be relevant for breast cancer, strikingly, 40% of the genes have been reported in the COSMIC top 20 genes for breast cancer.

Conclusions
Future development to better evaluate and assess our model will involve the inclusion of gene expression level, copy number variation, methylation, as well as including additional transcripts to be studied. Given that DeepCues is novel in its ability to utilize germline data in an informative manner, it will be of great interest and clinical impact to apply DeepCues to differentiate cancerous and non-cancerous samples. Disease classification
not only allows for improved diagnosis and therapies but also allows research to understand a disease through identified groups of genes and related pathways. DeepCues uses genetic sequencing data as inputs with little domain knowledge and feature preparation. With the abundance of genomic information available, we expect DeepCues can be used in a variety of disease settings to help profile diseases.

**Methods**

Due to the nature of 64 codons in human genetics, the input layer in component (A) uses one hot encoding to represent each input sequence as a N*64 binary matrix, where N equals the number of codons. Therefore, the input can be considered as a 1-D sequence with 64 channels. Component (B) is an encoder layer to encode the input to a lower dimensional vector. The encoder component contains a sequence of convolutional layers with six output channels and a fully connected layer for each output channel. Therefore, a vector of six outputs is generated by the encoder for each input sequence. In theory, the output channel can be set as any positive integer. The more output channel, the more expressive capacity and more complexity of the model. To make a trade-off between the complexity and the expressive capacity, we set the output channel as six. In fact, if the precision of each channel is 0.01 (i.e., can store 100 numbers), 6 channels can express 100^6 different samples. One convolutional layer is composed of one 1-D convolutional layer followed by a Leaky Rectified Linear Unit (LeakyReLU) as the activation function and an average pooling layer. The number of convolution layers is determined by the transcript length N and the kernel size for average pooling layer. A Kernel size of six was used for the average pooling. Therefore, we will have log_6N convolution layers for each transcript. Component (C) is a fully connected layer with k outputs for k diseases. The inputs of component (C) are the combinations of products from the component (B) generated under the sequence of transcripts. With the average of 3375 bases in the transcripts, the encoder layer would have an average of 3–4 convolution layers. Of note, we set the following parameters for our model: the number of input channels for the encoder layer: 64; the convolution kernel size: 3, the output channel size of the encoder layer: 3; learning rate: 0.001; batch size: 32; number of learning epochs: 30. We used cross entropy loss as the loss function and Adam algorithm as the optimizer.

A training set, validation set, and test set were created by randomly splitting the samples using a 7:1:2 ratio, respectively. Parameters were trained using the training set and tuned using the validation set. Precision, recall, and F-measure were calculated for each cancer type using the testing set. To compare the performance of our models to other conventional methods for cancer classification, we applied penalized logistic regression with L1 penalty, linear support vector machine (SVM), gradient boosting decision tree (GBDT), and Multiple Layer Perceptron (MLP) [14, 47]. Inputs for regression, SVM, GBDT are point mutations, whereas input for MLP are sequence data. The performance was also compared between the germline raw sequence and the cancer raw sequence. For the DeepCues, evaluations were repeated ten times with different initial seeds.

To reduce computational load, we selected genes that have been implicated in cancer using a list of 719 consensus genes (Additional file 1: Table S1) from the Catalogue of Somatic Mutations in Cancer (COSMIC). COSMIC is a mutation catalogue with comprehensive mutation information curated from about 542,000 tumor samples.
In our dataset, we found these consensus genes corresponded to 985 transcripts (Additional file 2: Table S2), and we used these transcripts to train and evaluate our proposed classifiers. We compared DeepCues with multiple conventional methods and state-of-the-art method, including penalized logistic regression (L1 penalty), SVM with linear kernel, Gradient Boosting Decision Tree (GBDT), and MLP model. The regression, SVM, and GBDT baseline model was trained using germline variants and somatic mutations found in these selected transcripts. Default parameters were used for the baseline models in scikit-learn (v0.22). To discover potentially relevant genes not known to be implicated in cancer, we also applied a multinomial logistic regression model to the remaining transcripts using disease type as an output, and the number of mutations in each transcript as inputs to identify the 985 top ranked transcripts based on p-value (Additional file 3: Table S3). The inputs for the multinomial are number of mutations in each transcript. The number of mutations has been normalized by gene length. Classifiers were trained, and evaluation was measured using only known pathogenic transcripts and also using a combination of the known and unknown pathogenic transcripts. It has been demonstrated that features frequently ranked high in different training sets yields a robust set of predictive features with stability [48]. To obtain a gene list with reasonable stability, we repeated training the classifiers with random seeds and reported the top 20 most frequent transcripts in each replication. An earlier version of this article was previously published as a preprint [49].

Abbreviations
CNNs: Convolutional neural networks; DeepCues: Deep learning for disease Classification using exome sequencings; TCGA: The Cancer Genome Atlas; COSMIC: Catalogue of somatic mutations in cancer; GBDT: Gradient Boosting Decision Tree; MLP: Multiple Layer Perceptron; LeakyReLU: Leaky Rectified Linear Unit; SVM: Support vector machine.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12859-021-04400-4.

Additional file 1 Table S1. 719 known oncogenes used in our pilot study
Additional file 2 Table S2. 985 transcripts corresponding to the 719 genes
Additional file 3 Table S3. 985 additional transcripts selected for analyses using multimodal logistic regression
Additional file 4 Table S4. Top genes in the 985 pathogenetic cancer transcripts
Additional file 5 Table S5. Top genes of the 985 pathogenetic germline transcripts
Additional file 6 Table S6. Top genes of the 1970 pathogenetic cancer transcripts
Additional file 7 Table S7. Top genes of the 1970 pathogenetic germline transcripts

Acknowledgements
We acknowledge the Center of Genomics Compute Cluster in Northwestern University for offering the computational resources and technical supports.

About this supplement
This article has been published as part of BMC Bioinformatics Volume 22 Supplement 4 2021: Accelerating Bioinformatics Research with ICIBM 2020 (part 2). The full contents of the supplement are available at https://bmcbioinformatics.biomedcentral.com/articles/supplements/volume-22-supplement-4.

Authors’ contributions
ZZ and YL originated the study. ZZ, CM, and YL performed analyses and wrote the first draft of the manuscript. CM, JON, and AV procured and curated the datasets. XL contributed to statistical analysis. SAK and SEC reviewed and helped analyze the findings. All authors discussed the results and revised the manuscript. All authors read and approved the final manuscript.
Funding
ZZ was supported in part by Breast Cancer Research Foundation and the Lynn Sage Cancer Research Foundation. The funding bodies did not play any role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. Publication costs are funded by Northwestern University Feinberg School of Medicine.

Availability of data and materials
Somatic mutations and aligned sequence files (bam files) for germline variants generation are available upon application to the access controlled TCGA data (https://portal.gdc.cancer.gov) through database of Genotypes and Phenotypes (dbGap) application. The proposal and data application have been approved by dbGap application. All codes necessary to process the sequencing data and to re-generate the results are publicly available at https://github.com/zexian/DeepCues.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors have no competing interests to declare.

Author details
1Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 750 N Lake Shore Drive Room 11-189, Chicago, IL 60611, USA. 2Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 3Committee on Developmental Biology and Regenerative Medicine, The University of Chicago, Chicago, IL, USA. 4Tsinghua University, Beijing, China. 5Research Computing Services, Northwestern University, Chicago, IL, USA. 6Department of Surgery, Feinberg School of Medicine, Northwestern University, NMH/Prentice Women’s Hospital Room 4-420 250 E Superior, Chicago, IL 60611, USA. 7Department of Surgery, Feinberg School of Medicine, Northwestern University, Robert H Lurie Medical Research Center Room 4-113 250 E Superior, Chicago, IL 60611, USA.

Received: 12 September 2021   Accepted: 24 September 2021
Published: 25 October 2021

References
1. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. A census of human cancer genes. Nat Rev Cancer. 2004;4(3):177.
2. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173(2):371-385.e318.
3. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719.
4. Rischi NJ. Searching for genetic determinants in the new millennium. Nature. 2000;405(6788):847–56.
5. Leiserson MD, Blokh D, Sharan R, Raphael BJ. Simultaneous identification of multiple driver pathways in cancer. PLoS Comput Biol. 2013;9(5):e1003054.
6. Melamed RD, Wang J, Iavarone A, Rabadar B. An information theoretic method to identify combinations of genomic alterations that promote glioblastoma. J Mol Cell Biol. 2015;7(3):203–13.
7. Luo Y, Reddinger G, Szolovits P. Text mining in cancer gene and pathway prioritization. Cancer Inform. 2014;13(Suppl. 1):169.
8. Zeng Z, Vo A, Li X, Shifdar A, Saldana P, Blanco L, Xuei X, Luo Y, Khan SA, Clare SE. Somatic genetic aberrations in benign breast disease and the risk of subsequent breast cancer. NPJ Breast Cancer. 2020;6(1):1–11.
9. Cai J, Ye Q, Luo S, Zhuang Z, He K, Zhuo Z-J, Wan X, Cheng J. CASP8-652 6N insertion/deletion polymorphism and overall cancer risk: evidence from 49 studies. Oncotarget. 2017;8(34):36780.
10. Li C, Feng L, Niu L, Li TT, Zhang B, Wan H, Zhu Z, Liu H, Wang K, Fu H. An insertion/deletion polymorphism within the promoter of EGLN2 is associated with susceptibility to colorectal cancer. Int J Biol Markers. 2017;32(3):274–7.
11. Cui Y, Cheng X, Chen Q, Song B, Chiu A, Gao Y, Dawson T, Chao L, Zhang W, Li D. CRISP-view: a database of functional genetic screens spanning multiple phenotypes. Nucleic Acids Res. 2021;49(D1):D848–54.
12. Gu SS, Wang X, Hu X, Jiang P, Li Z, Traugh N, Bu X, Tang Q, Wang C, Zeng Z. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biol. 2020;21(1):1–28.
13. Domingos P, Pazzani M. Beyond independence: conditions for the optimality of the simple Bayesian classifier. In: Proc 13th int conf machine learning; 1996. p. 105–112.
14. Ravikumar P, Wainwright MJ, Lafferty JD. High-dimensional Ising model selection using $\ell_1$-regularized logistic regression. Ann Stat. 2010;38(3):1287–319.
15. Zeng Z, Amin A, Roy A, Pulliam NE, Karavites LC, Espino S, Helenowski I, Li X, Luo Y, Khan SA. Preoperative magnetic resonance imaging use and oncologic outcomes in premenopausal breast cancer patients. NPJ Breast Cancer. 2020;6(1):1–8.
16. Zhang S, Cheng D, Deng Z, Zong M, Deng X. A novel kNN algorithm with data-driven k parameter computation. Pattern Recognit Lett. 2018;109:44–54.
17. Miotti R, Wang F, Wang S, Jiang X, Dudley JT. Deep learning for healthcare: review, opportunities and challenges. Brief Bioinform. 2018;19(6):1236–46.
18. Zhang Y, Manjunath M, Zhang S, Chasman D, Roy S, Song JS. Integrative genomic analysis predicts causative cis-regulatory mechanisms of the breast cancer-associated genetic variant rs4415084. Can. Res. 2018;78(7):1579–91.

19. Zhang Y, Manjunath M, Yan J, Baur BA, Zhang S, Roy S, Song JS. The cancer-associated genetic variant Rs3903072 modulates immune cells in the tumor microenvironment. Front. Genet. 2019;10:754.

20. LeGurn Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436.

21. Mamoshina P, Veira A, Putin E, Zhavoronkov A. Applications of deep learning in biomedicine. Mol Pharm. 2016;13(5):1445–54.

22. Angermueller C, Parnamaa T, Parts L, Stegle O. Deep learning for computational biology. Mol Syst Biol. 2016;12(7):878.

23. Mao C, Yao L, Pan Y, Luo Y, Zeng Z. Deep generative classifiers for thoracic disease diagnosis with chest x-ray images. In: 2018. IEEE. p. 1209–1214.

24. LeCun Y, Bottou L, Bengio Y, Haffner P. Gradient-based learning applied to document recognition. Proc IEEE. 1998;86(11):2278–324.

25. Alipanahi B, Delong A, Weirauch MT, Frey BJ. Predicting the sequence specificities of DNA-and RNA-binding proteins by deep learning. Nat Biotechnol. 2015;33(8):831.

26. Quang D, Xie X. DanQ: a hybrid convolutional and recurrent deep neural network for quantifying the function of DNA sequences. Nucleic Acids Res. 2016;44(11):e107–e107.

27. Zhou J, Troyanskaya OG. Predicting effects of noncoding variants with deep learning-based sequence model. Nat Methods. 2015;12(10):931.

28. Angermueller C, Lee HJ, Reik W, Stegle O. DeepCpG: accurate prediction of single-cell DNA methylation states using deep learning. Genome Biol. 2017;18(1):1–13.

29. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM, Network CGAR. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113.

30. Mckenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303.

31. Cingolani P, Platts A, Le Wang L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 2012;6(2):80–92.

32. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(Database issue):D945–950.

33. Grantham R. Amino acid difference formula to help explain protein evolution. Science. 1974;185(4154):869–72.

34. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89(1):82–93.

35. Alipanahi B, Delong A, Weirauch MT, Frey BJ. Predicting the sequence specificities of DNA-and RNA-binding proteins by deep learning. Nat Biotechnol. 2015;33(8):831.

36. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89(1):82–93.

37. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science (New York, NY). 2004;305(5685):869–72.

38. Fearnhead NS, Wilding JL, Winney B, Tonks S, Bartlett S, Bicknell DC, Tomlinson IP, Mortensen NJM, Bodmer WF. Multiple rare variants in different genes account for multifactorial inherited susceptibility to colorectal adenomas. Proc Natl Acad Sci. 2004;101(45):15992–7.

39. Saha KP, Szczurek E, Sakoparnig T, Beerenwinkel N. Predicting cancer type from tumour DNA signatures. Genome Med. 2017;9(1):104.

40. Madsen BE, Browning SR. A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet. 2009;5(2):e1000384.

41. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89(1):82–93.

42. Angermueller C, Pärnamaa T, Parts L, Stegle O. Deep learning for computational biology. Mol Syst Biol. 2016;12(7):878.

43. Mao C, Vo A, Nugent JO, Khan SA, Clare SE, Luo Y. Deep learning for cancer type classification. bioRxiv 2019;612762.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.